Results 21 to 30 of about 6,119 (209)

Esketamine Preserves Network Connectivity and Promotes Recovery in Consciousness Disorders. [PDF]

CNS Neurosci Ther
Esketamine anesthesia promotes consciousness recovery in patients with disorders of consciousness by preserving brain network complexity and connectivity during surgery. Compared to propofol, esketamine facilitates superior neurophysiological preservation and shows a strong trend toward improved long‐term clinical outcomes.
Qin X, Chen X, Yao L, Wang B, Niu H, Liang Z, Zhao Z, Wang J, Huang J, Guo X, Li X.   +10 more
europepmc   +2 more sources

Esketamine improves propofol-induced brain injury and cognitive impairment in rats

Translational Neuroscience, 2022
As an intravenous anesthetic, propofol has been indicated to induce neurotoxicity in both animal and human brains. It is of great significance to better understand the potential mechanism of propofol-induced neurotoxicity to eliminate the side effects of
Xu Guiping, Wang Yang, Chen Zhe, Zhang Yuxuan, Zhang Xuexue, Zhang Guichao   +5 more
doaj   +1 more source

ESKALE study, a French real-world study describing TRD patients with Esketamine nasal spray: final analysis

European Psychiatry, 2023
Introduction Treatment resistant depression (TRD) affects a substantial proportion of patients with depression and carries a large unmet need. Esketamine nasal spray (NS), in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin ...
L. Samalin, L. Mekaoui, M. Rotharmel, P. de Maricourt, M.-A. Codet, E. Gaudre Wattinne   +5 more
doaj   +1 more source

Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries

Middle East Current Psychiatry, 2023
Background There is a high unmet need among patients with treatment-resistant depression (TRD) as treatment with standard therapies is associated with low response and remission rates and high rates of relapse.
Nahida Nayaz Ahmed, Faisal Albishi, Suhail A. Khan, Ammar Alsayegh, Emmanuel Stip, Samer Makhoul   +5 more
doaj   +1 more source

A Clinical Rationale for Assessing the Impact of Childhood Sexual Abuse on Adjunctive Subcutaneous Esketamine for Treatment-Resistant Depression

Frontiers in Psychiatry, 2021
Background: A history of child sexual abuse (CSA) is related to higher suicide rates and poor treatment outcomes in depressed adult patients. Twenty years after the first study investigating the effects of ketamine/esketamine on depression and suicide ...
Eduardo Jorge Muniz Magalhães, Luciana Maria Sarin, Lorena Catarina Del Sant, Ana Cecília Lucchese, Carolina Nakahira, Marco Aurélio Tuena, Camila Brito Puertas, Victor Augusto Rodovalho Fava, Rodrigo Simonini Delfino, Rodrigo Simonini Delfino, Juliana Surjan, Juliana Surjan, Matheus Souza Steglich, Matheus Souza Steglich, Matheus Ghossain Barbosa, Guilherme Abdo, José Alberto Del Porto, José Alberto Del Porto, Charles B. Nemeroff, Hugo Cogo-Moreira, Hugo Cogo-Moreira, Acioly Luiz Tavares Lacerda, Acioly Luiz Tavares Lacerda, Acioly Luiz Tavares Lacerda, Acioly Luiz Tavares Lacerda, Andrea Feijo Mello, Andrea Feijo Mello   +26 more
doaj   +1 more source

Esketamine for treatment-resistant depression in adults

, 2022
Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. The main aim of this Cochrane review is to assess the efficacy and tolerability of esketamine for treatment-resistant depression.
Barbui C., Papola D., Cristea I. A., Laurenzi P. F., Naudet F., Ostuzzi G., Gastaldon C., Schoretsanitis G.   +7 more
core   +2 more sources

Safety of esketamine nasal spray: Analysis of post-marketing reports submitted to the FDA adverse event reporting system in the first year on the market

European Psychiatry, 2021
Introduction The approval of the esketamine nasal spray for treatment-resistant depression in March 2019 by the Food and Drug Administration (FDA), and few months later by the European Medicine Agency, triggered a vivid debate and many concerns, mainly
C. Gastaldon, E. Raschi, J. Kane, C. Barbui   +3 more
doaj   +1 more source

Electroconvulsive therapy vs Esketamine among patients with Major Depressive Episode

European Psychiatry, 2023
Introduction Major depressive disorder is one of the most common and disabling mental disorders. More than 30% of individuals do not achieve remission after several trials of antidepressants and treatment-resistant depression (TRD) is associated with ...
M. D. R. D. R. F. D. A. Basto, O. Nombora, L. Santa Marinha, J. L. Simães, A. Horta   +4 more
doaj   +1 more source

Therapeutic environment for esketamine a policy [PDF]

, 2023
This project aimed to develop a structured policy surrounding the therapeutic environment of esketamine to provide continuity of care and maximize therapeutic benefits while mitigating possible side effects of esketamine. A literature review for the most
Stewart, Sierra
core   +1 more source

Esketamine nasal spray compassionate use program in the Netherlands: An open label, multi-center cohort study in severe treatment-resistant depression

Journal of Affective Disorders Reports
Background: Esketamine, a N-methyl-d-aspartate (NMDA) receptor antagonist, used intranasally (IN), is applied as an antidepressant (AD) in treatment-resistant depressed (TRD) patients. Real-world studies with IN esketamine are still scarce.
Abel (K.A.J.) Busz, Emma (E.J.) Schmidt, Rob (R.H.S.) van den Brink, Karen (K.) Foeken, Marasha (M.) de Jong, Joost (J.B.C.) Mertens, Martijn (M.S.) van Noorden, Etienne (E.J.F.L.) Olivier, Koen (K.R.J.) Schruers, Sara (S.I.J.) Schutters, Joris (J.) van Son, Wessel (W.J.) Strootker, Harry (H.C.P.) Venema, Dieuwertje (D.A.) de Waardt, Jasper (J.B.) Zantvoord, Danielle (D.) Cath, Henricus (H.G.) Ruhe   +16 more
doaj   +1 more source